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The Role of Specimen Banking in
RiskAssessment
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The risk assessment process is described with a focus on the hazard identification and dose-response components. Many of the scientific ques-
tions and uncertainties associated with these components are discussed, and the role for biomarkers and specimen banking in supporting these
activities are assessed. Under hazard identification, the use of biomarkers in defining and predicting a) biologically adverse events; b) the progression
of those events towards disease; and c) the potential for reversibility are explored. Biomarker applications to address high-to-low dose extrapolation
and interindividual variability are covered under dose-response assessment. Several potential applications for specimen banking are proposed.
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Background
As citizens, we are all concerned that our
health, and the health of our children could
be compromised or endangered by exposure
to toxic chemicals and other potential health
hazards in the air we breathe, and in our food
and drinking water. Public concern over this
potential for harm resulting from exposure to
environmental pollutants has led to ademand
for protection from environmental risk, either
real or imagined. This demand has prompted
public health officials, environmental scien-
tists, and regulatory agencies to pursue
processes to define, explain, and mediate
environmentally related health risks (1,2).
The U.S. Environmental Protection Agency
(U.S. EPA) has responded to public demand
by adopting a paradigm that was proposed
initially by the National Academy ofSciences
(NAS) (3). This approach to risk assessment
provides a format and data for estimating the
potential adverse health effects ofhuman
exposures to environmental hazards that, in
turn, provides the cornerstone to risk man-
agement decisions (Figure 1). In this article,
selective components ofthis risk assessment
process are described as well as some ofthe
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scientific questions and uncertainties that
accompany these components. The role for
biomarkers and specimen banking in this
process will be assessed. The discussion
focuses on issues related to human exposure
and health assessment rather than the broader
role ofbiomarkers in toxicology (e.g., mecha-
nistic studies in animals). Although much has
been written on the contribution ofbiomark-
ers to riskassessment, the challenge to partici-
pants in this symposium is to define the
potential contributions to be gained from
specimenbankingactivities.
Although this paper is focused on risk
assessment, itshould be recognized that infor-
mation required for this process is also critical
for numerous other collateral and interrelated
activities and actions that support risk man-
agement decisions. Biomarkers and specimen
banking may also contribute to these activi-
ties, and, in fact, their role may be even more
apparent in these other contexts. For exam-
ple, information derived from activities that
may be referred to as monitoring (exposures)
or surveillance (health status and trends) are
essential to establishing baseline (reference)
values, directing pollution prevention
options, assessing the efficacy ofcorrective
actions, or anticipating/detecting emerging
environmental problems. Such data when
combined with risk assessment activities may
also help define and prioritize the legitimate
environmental risks for the public. This
approach can, in turn, ensure thatpublic and
private attention, expertise, and resources are
directed appropriately. An appreciation ofthe
interplay between these collateral activities
and risk assessment should be incorporated
into defining the role and criteria for
biomarkers and specimen banking activities
purported to support theseprocesses.
RISK ASSESSMENT
Figure 1. Components of the risk assessment process
and the interface with risk management.
For this paper, biomarkerwill be defined
"as any measurable biochemical, physiologi-
cal, cytological, morphological, or other bio-
logical parameter obtainable from human
tissues, fluid, or expired gases, that is associ-
ated (directly or indirectly) with exposure to
an environmental pollutant" (4).
The Risk Assessment Process
Simply defined, risk assessment is the
attempt to understand the relationship
between human exposures and potential
health effects. This understanding requires
identifying the factors that result in human
exposure and then defining the cascade of
events that must occur to create a health
risk. This analysis entails delineating the
pharmacokinetic and pharmacodynamic
processes that govern this cascade. As pre-
sented in Figure 2, biomarkers research has
separated historically this continuum into
exposure and health compartments. More
contemporary efforts have acknowledged
that biomarkers ofdose can serve as the
common denominator for linking these
Environmental Health Perspectives 9ZENICKAND GRIFFITH
HISTORICAL >
CURRENT >--<
FUTURE <
Figure 2. Cascade of events between human exposure
and health effects and the historical, current, and
future focus of biomarkers research.
events. Future efforts should approach
understanding these events from a contin-
uum perspective.
The NAS risk assessment paradigm
defines four components that can be over-
laid on this continuum (Figure 3):
HazardIdentification. Does the agent
cause an adverse effect?
Dose-ResponeAesnent What is the rela-
tionship between dose and occurrence/magni-
tudeofhealtheffects inhumans?
Exposure Assessment. What exposures
are experienced currently or anticipated
under different conditions?
Risk Characterization. What is the esti-
mated occurrence/magnitude of the
[adverse] effect in a given population?
Conventionally (and conveniently) bio-
markers can be defined by three, interrelated
categories, namely, biomarkers of exposure,
effect, and susceptibility that can be related
to the components of the risk assessment
process. These relationships are discussed in
the following sections. Since much ofthis
symposium is devoted to human exposure,
the focus of this paper will be primarily
on biomarkers as they relate to hazard
identification and dose-response assessment.
Biomarkers and Hazard
Identification
Hazard identification defines whether an
agent can cause an adverse effect and its rele-
vance to human health and disease. This
evaluation examines all available data includ-
ing human, test species, and in vitro data
with close scrutiny to dose-response and
Envlronnmmital Human Hafth
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dose-effect relationships. Conclusions as to
the hazard potential for a given agent are
based upon aweight-of-evidence summation.
There are several issues that must be
addressed in hazard identification in which
human biomarker data could contribute
(Table 1). Perhaps most critical is understand-
ing the biologic significance ofbiomarker(s)
ofeffect whose occurrence can be measured at
verylow exposure levels. Because ofincreasing
evolution and sophistication in measurement
methods and instrumentation, changes in
baseline levels can be detected more readily.
Given an appropriate study design, these
changes maybe found to bestatistically signif-
icant. Less certain iswhether these biomarkers
represent an adverse, or potentially adverse
event, i.e., their value in predicting human
health disease or dysfunction. (For the
remainder ofthis paper, "disease" will be used
to imply either a dysfunctional state or actual
disease.) An example of a success story is
blood lead levels in children and the demon-
strated relationship to neurotoxicity that has
provided key information for the existinglead
standard. On the other hand, the biologic sig-
nificance ofmoderate changes in plasma and
red blood cell levels ofacetylcholinesterase
(AchE) remains uncertain. Although widely
accepted as abiomarker ofexposure to certain
dasses ofpesticides, the role ofperipheral lev-
els ofAchE in predicting toxicity to the
central nervous system (CNS) is less dear.
Ideally, biomarker(s) ofeffect should pro-
vide insight into current health status and, if
present, the stage ofthe disease. An under-
standing ofthe potential for reversibility asso-
ciated with a decrease or discontinuation of
exposure is equally important. Biomarkers of
reversibility however, must distinguish
between true recovery (absence ofpollutant-
induced effects) and the failure to detect
adverse effects as a result ofadaptation orbio-
logic compensation which may mask existing
impairment. There is also a need to under-
stand the relationship between the current
biomarker and silent processes that may
underlie the [eventual] appearance ofdisease.
The common denominator for a biomarker
ofeffect that provides information on the
latency, stage and progression, and reversibil-
ity is an understanding of the putative
mechanisms ofthe disease understudy.
Potentially, biomarkers may also play a
role in determining if a threshold exists, and,
Table 2. Examples of exposure-effect scenarios.
Table 1. Potential roles for biomarkers in hazard iden-
tification.
Defining biologic significance of low-dose effects
Adversity
Predictive validity
Defining stage of disease/dysfunction
Latency
Progression
Reversibility
Acclimation/compensation
Defining threshold(s)
if so, what level of exposure is necessary to
exceed that threshold and pose a health risk.
Equally important is whether this threshold
varies for different populations (e.g., young
vs adult, rural vs urban). Biomarkers that can
identify/distinguish these populations may
impact dramatically health risk assessment
and risk management decisions.
Biomarkers and Dose-
Response Assessment
Critical to any risk assessment is an under-
standing between exposure (dose) and the
occurrence/magnitude ofadverse effects.
Ideally, this relationship would be approxi-
matelylinear (i.e., increasingriskwith increas-
ing exposure). However, depending on the
target and its inherent properties to respond
to toxicity (e.g., repair), a matrix of exposure
and effects scenarios is more likely (Table 2).
The situation becomes more complicated
when an individual operates concurrently
under more than one exposure situation (e.g.,
chronic, low-level exposure with periodic high
excursions) and experiences multi-chemical
exposures. The use ofbiomarkers ofdose and
pharmacokinetic modeling offers great
promise for better defining exposure
(dose)-response relationships.
Henderson et al. (5) have proposed that a
suite ofbiomarkers be employed to reflect
recent aswell as pastand, potentially, cumula-
tive exposures. Such a suite would accommo-
datevarying rates ofdisposition (e.g., different
half-lifes) of the parent compound, its
metabolites, and any other surrogate markers
that reflect an interaction between the agent
and abiologic target (Figure 4). Yet, as seen in
Figure 5, even an accurate estimate ofdose
may notpredict effect status. Again, an under-
standing ofthe pharmacokinetic behavior
of an agent must be synthesized with
Exposure Transient Prolonged Static Progressive/cumulative
Acute X X - -
Intermittent X X X X
Subchronic/chronic X - X X
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Figure 3. Relationship of risk assessment components
to the cascade from exposure to health effects.
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Figure4. Potential, relative levels ofvarious biomarkers with time after exposure (5).
hypotheses/insights into the processes and
mechanisms ofthe disease in question to pro-
vide biologically plausible dose-response
assessments.
Although such biologically based mod-
els are desirable, such approaches, to date,
have had limited application, primarily
focused on cancer and favoring a no thresh-
old hypothesis (i.e., the interaction ofa sin-
gle molecule in a single cell will result in an
adverse effect). The prospect of nongeno-
toxic, carcinogenic mechanisms has sug-
gested that thresholds may, in fact, exist for
certain environmental carcinogens.
A threshold is assumed to exist for most
noncancer health effects. That is, there is a
range ofexposures from zero to some finite
level that can be tolerated with essentially no
adverse effect. These assessments most often
relyon defining a no observable adverse effect
level (NOAEL) or a lowest observable adverse
effect level (LOAEL) from the available data.
This estimate is then adjusted downward by
application ofa series ofuncertaintyfactors to
Progressive
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Figure 5. Varied time-effects scenarios even with the
concentration of an agent atsteadystate(heavydark line).
provide a conservative estimate ofan exposure
(dose)'level which poses no human health
risk. This process ofdefining a LOAEL or
NOAEL and applying uncertainty factors
(Table 3) produces what is now widely
termed a reference dose (RfD) or reference
concentration (RfC) depending on whether
the exposure route is oral or inhalation,
respectively. For purposes ofthis paper, dis-
cussion will focus on the uncertainties associ-
ated with high-to-low dose extrapolation and
the across human (interindividual) variability.
Irrespective ofwhether biologic modeling or
an RfD/RfC approach is employed, uncer-
tainties associated with these two factors will
be present. Biomarkers mayhave asubstantial
role in determining the necessity and/or
magnitudeofthese uncertaintyfactors.
High-to-LowDoseExtapolation
Although human health data for the expo-
sure situation ofconcern is what is desired,
the majority ofdata on which human risk
assessments are based is derived from test
species or humans in elevated exposure set-
tings (e.g., occupational). The riskassessor is
then required to determine risk for individ-
uals operating in environments character-
ized by much lower exposures. The shape
and slope of the curve of a dose-response
Table 3. Uncertainty factors generally considered in
developing an RfD/RfC.
Tenfold Within human variability
Tenfold Animal to human variability
Tenfold Subchronic to chronic exposure
Tenfold LOAEL to NOAEL
<1 -tenfold Modifying factorfor other uncertainties
model or the nature and magnitude of
uncertainty factors applied to a NOAEL are
related directly to the confidence that the
targets and mechanisms underlying the toxic
response in the test species are comparable
in humans and that those mechanisms can
be triggered at the lower doses associated
with environmental exposures.
The tendency historically has been to
accept these assumptions with research then
focused on identifying biomarkers ofmecha-
nism and dose present at low exposure levels.
This approach assumes implicitlyalinear rela-
tionship between dose and risk. Perhaps a
more systematic approach would be to iden-
tify biomarkers nearer the dose range ofthe
experimental data and then progress in a
descending, steplike fashion toward the
human exposure range ofconcern. Thus, ini-
tial efforts would compare biomarkers from
humans with exposures dosest to the experi-
mental data (Figure 6). Such datawould most
often comefrom theoccupational setting.
High-to-low dose extrapolations may
assume initially that the highest exposed
individuals are biologically representative of
the general population and differ only in
terms of exposure. Clearly, other factors
pose limitations to this overall generaliza-
tion. For example, the healthy worker effect
in occupational settings may produce expo-
sure-response data that underestimate
health risk for the general population even
at lower exposures. Conversely, ifthe high-
est exposed also represents groups with com-
promised health status (e.g., the poor, the
elderly), extrapolation may overestimate the
effect(s) for the general population.
InterndividualVariability
The examples presented above may be con-
sidered to be a subset ofthe many factors
associated with interindividual variability in
response (i.e., biomarker) in a given envi-
ronmental setting. Other terms often used
Exposure (Dose)
Figure 6. Overlay of a possible human exposure distrib-
ution on the extrapolated dose-risk curve (dashed line).
The band demarcated by vertical lines represents a
human subgroup with the highest exposures. The ques-
tion mark reflects uncertainty as to the shape of the
actual curve belowthe observed data.
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to account for interindividual variability are
differences in sensitivity or susceptibility of
the individual or subpopulation to a specific
environmental insult. Whether these phe-
nomena, in fact, reflect the same, underly-
ing biologic processes is debatable and
certainly has ramifications for interpretation
ofbiomarker data. However, this question
could serve as the basis for the entire sympo-
sium andwill not be addressed in this paper.
The major premise is that, although indi-
viduals may experience similar environmental
exposures, individual differences inpharmaco-
kinetic or pharmacodynamic processes may
greatly influence the dose that reaches the tar-
get site and/or the degreeofresponse. Anum-
ber offactors including age, diet, and health
status will obviously influence these processes.
Increased or decreased responsiveness (suscep-
tibility) may also be acquired wherein previ-
ous exposures sensitize the individual to
subsequent exposures. An immunologic basis
islikelyforthis phenomena.
However, genetic predisposition seems
to be the major determinant. For example,
inherited differences in metabolic capabili-
ties (e.g., polymorphism for activating/deac-
tivating enzymes) can greatly influence the
concentration and maintenance ofthe bio-
logically effective dose at the target site.
Similarly, genetic differences in repair or
compensatory mechanisms, reserve capacity,
and other biologic processes may influence
the magnitude ofthe toxic response.
The existence of interindividual vari-
ability in response implies that the individ-
uals at greatest health risk may not be
synonymous with those that experience the
greatest exposures. The interplay between
these two distributions is not well under-
stood (Figure 7). Biomarkers that provide
such insights will greatly assist efforts to
quantify human risk estimations.
The Role ofTissue Banking
Based upon the preceding discussion, bio-
markers ofexposure, effect, and susceptibility
would appear to have major roles in improv-
ing risk assessments. How the retention and
preservation ofthesesamples (specimen bank-
ing) may further enhance these estimations is
IC
Figure 7. Interplay between exposure and responsive-
ness population distributions.
less dear. Moreover, the application will usu-
ally be retrospective, i.e., banking specimens
today that may improve, refine, or reaffirm a
risk assessment addressed in the future. Such
an application places atremendous burden on
the population sampling design for a speci-
men bank since it is critical that individuals/
groups sampled today be representative ofthe
exposed population in which disease is
observed in the future. Some potential, inter-
related applications can be offered that have
implications for hazard identification and
dose-response assessment.
a) Reaffirm biologic significance/predic-
tive validity: This application requires retro-
spective comparisons, namely, determining
the relationship between previously obtained
biomarker(s) and current exposure/health sta-
tus. The ability ofspecific biomarkers to pre-
dict disease progression and reversibility may
also be ascertained. Such evaluations would
allow greater confidence to be placed on pre-
dinical, low dose biomarkers as the basis for a
riskassessment in theabsenceoffrankdisease.
b) Provide historical baseline (reference)
values: The ability to ascertain whether an
agent has elevated health risk can be strength-
ened bycomparison to concurrent controlval-
ues which have been placed in the context of
historical values. This comparison ofcontrol
cohorts may allow for the discrimination and
quantification oftemporal versus pollutant-
inducedchanges inagivenhealthmeasure.
c) Reassess mechanistic hypotheses: As
notedpreviouslyin this paper, identifyingand
understanding pharmacokinetic and pharma-
codynamic mechanisms are key to ensuring
more biologically sound risk assessments.
Specimen banking may allow the retrospec-
tive testing ofhypotheses regarding putative
mechanisms for diseases, especially those with
long latencies. Again, the current and future
cohorts must be similar enough to allow such
linkages to be valid. This application is facili-
tated ifthe specimens were obtained on the
actual target tissues (e.g., lung, liver, etc.), or if
concentrations in biologic fluids have been
demonstrated to trulyreflect targetdose.
d) Confirming exposure-dose effects link-
ages under changing exposure scenarios: As
exposure conditions ofa population or sub-
group change over time a corresponding
change in health status (i.e., biomarker values)
should occur ifpreviouslyhypothesized associ-
ations andattendantriskestimations arevalid.
e) Identifying new high risk groups:
Factors that may elevate the risk to an envi-
ronmental pollutant for certain individuals or
subgroups (e.g., increased exposures; increased
susceptibility) will impact the risk assessment
forthat agent. Banked specimens mayprovide
the referents to aidsuch identification.
Conclusions
The concept oftissue banking is to provide
for the long-term storage ofbiologic speci-
mens. The premise is that a bank oftissue
samples, collected and archived appropri-
ately, provides scientifically preserved and
documented samples for retrospective and
prospective cohort studies. This resource,
by providing human material, would also
seem to hold great promise for reducing
many of the uncertainties associated with
assessing the health risks associated with
exposure to environmental pollutants.
Thedesignand implementation ofaspeci-
men bankshould benefit from participation of
diverse areas within the scientific community
(e.g., epidemiologists, toxicologists, industrial
hygienists, statisticians, riskassessors, etc). This
broad input is critical to determine whether a
design for specimen banking can be developed
that will accommodate divergent interests/
needs within the public health community.
To that extent, the compatibility ofriskassess-
ment needs relative to other applications will
requirefurtherexploration.
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